VERAXA Biotech AG (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback that supports the company's proposed development strategy for its lead BiTAC(R)-TCE program. This early guidance from PEI addresses the biological rationale, safety assessments, and non-clinical development plan for the novel therapeutic platform, helping to reduce development uncertainty before the company advances toward clinical studies (https://ibn.fm/zBiDU).
The BiTAC(R)-TCE platform represents VERAXA's proprietary bispecific T-cell engager technology, designed to redirect the immune system to target and eliminate cancer cells. The company's lead candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The regulatory milestone follows continued progress in manufacturing and development as VERAXA advances next-generation antibody therapeutics for oncology.
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy. By obtaining this feedback from PEI, VERAXA gains greater clarity on the non-clinical requirements needed to support an eventual clinical trial application, potentially streamlining the path to first-in-human studies.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The company is focused on designing novel cancer therapies that leverage its proprietary platforms to address unmet medical needs. The positive regulatory interaction with PEI underscores the potential of the BiTAC(R)-TCE approach and provides a foundation for future development milestones.
Investors and stakeholders can find the latest news and updates relating to VERAXA in the company's newsroom at https://ibn.fm/VRXA. As VERAXA progresses its lead program toward the clinic, the regulatory feedback from Germany's Paul-Ehrlich-Institute serves as an important validation of the company's scientific strategy and development planning.
